USCBC Comments on the Four Announcements on Relevant Policies for Encouraging Innovation in Drugs and Medical Devices

The US-China Business Council (USCBC) represents approximately 200 member companies engaged in business across all industries and sectors in China, including manufacturers and marketers of pharmaceutical and medical device products. USCBC appreciates the opportunity to submit comments on the China Food and Drug Administration (CFDA) Relevant Policies on Accelerating Review and Approval for New Drugs and Medical Devices to Encourage New Drug and Medical Device Innovation (“Circular No. 52”); Relevant Policies on Reforming Clinical Trial Management to Encourage New Drug and Medical Device Innovation (“Circular No. 53”); Relevant Policies on Implementing Life-Cycle Management for New Drugs and Medical Devices to Encourage New Drug and Medical Device Innovation (“Circular No. 54”); and Relevant Policies on Protecting Innovators’ Rights to Encourage New Drug and Medical Device Innovation (“Circular No. 55”)—collectively “the Draft Policies”, as published on May 11-12, 2017.

Read the full letter here.